Top

02-06-2018 | Post-transplant diabetes mellitus | Review | Article

Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment

Journal: Diabetes Therapy

Authors: Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil

Publisher: Springer Healthcare

Abstract

Post-liver transplantation diabetes mellitus (PLTDM) develops in up to 30% of liver transplant recipients and is associated with increased risk of mortality and multiple morbid outcomes. PLTDM is a multicausal disorder, but the main risk factor is the use of immunosuppressive agents of the calcineurin inhibitor (CNI) family (tacrolimus and cyclosporine). Additional factors, such as pre-transplant overweight, nonalcoholic steatohepatitis and hepatitis C virus infection, may further increase risk of developing PLTDM. A diagnosis of PLTDM should be established only after doses of CNI and steroids are stable and the post-operative stress has been overcome. The predominant defect induced by CNI is insulin secretory dysfunction. Plasma glucose control must start immediately after the transplant procedure in order to improve long-term results for both patient and transplant. Among the better known antidiabetics, metformin and DPP-4 inhibitors have a particularly benign profile in the PLTDM context and are the preferred oral agents for long-term management. Insulin therapy is also an effective approach that addresses the prevailing pathophysiological defect of the disorder. There is still insufficient evidence about the impact of newer families of antidiabetics (GLP-1 agonists, SGLT-2 inhibitors) on PLTDM. In this review, we summarize current knowledge on the epidemiology, pathogenesis, course of disease and medical management of PLTDM.

United Network for Organ Sharing. Transplants by organ type. Richmond, VA, USA: United Network for Organ Sharing. https://www.unos.org/data/transplant-trends/. Accessed 21 Nov 2017.

Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675–88.PubMedCrossRef

Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The outcomes of adult liver transplants in the United States from 1987 to 2013. Liver Int. 2015;35:2036–41.PubMedCrossRef

Meirelles Júnior RF, Salvalaggio P, Rezende MB, Evangelista AS, Guardia BD, Matielo CE, et al. Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015;13:149–52.CrossRef

Salvalaggio PR, Caicedo JC, de Albuquerque LC, Contreras A, Garcia VD, Felga GE, et al. Liver transplantation in Latin America: the state-of-the-art and future trends. Transplantation. 2014;98:241–6.PubMedCrossRef

World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.PubMedCrossRef

WHO mortality database (online database). Geneva: World Health Organization. http://apps.who.int/healthinfo/statistics/mortality/causeofdeath_query/. Accessed 21 Nov 2017.

International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

10.

Lv C, Zhang Y, Chen X, Huang X, Xue M, Sun Q et al. New-onset diabetes after liver transplantation and its impact on complications and patient survival. J Diabetes. 2015;7:881–90.PubMedCrossRef

11.

Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992–2000.PubMedPubMedCentralCrossRef

12.

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation, 2006. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 31 Oct 2017.

13.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.PubMedCrossRef

14.

Honda M, Asonuma K, Hayashida S, Suda H, Ohya Y, Lee K-J, et al. Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients. Clin Transplant. 2013;27:426.PubMedCrossRef

15.

Hartog H, May CJ, Corbett C, Phillips A, Tomlinson JW, Mergental H, et al. Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury. Liver Int. 2015;35:1739–47.PubMedCrossRef

16.

Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 2004;10:349–55.PubMedCrossRef

17.

Soule JL, Olyaei AJ, Boslaugh TA, Busch AM, Schwartz JM, Morehouse SH, et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg. 2005;189:552–7.PubMedCrossRef

18.

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7.CrossRef

19.

Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN database. J Transplant. 2013;2013:269096.PubMedPubMedCentralCrossRef

20.

Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the organ procurement and transplant network/united network for organ sharing database. Transplantation. 2010;89:1134–40.PubMedCrossRef

21.

Yagi S, Kaido T, Iida T, Yoshizawa A, Okajima H, Uemoto S. New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function. Surg Today. 2017;47:733–42.PubMedCrossRef

22.

Van Laecke S, Desideri F, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X, et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl. 2010;16:1278–87.PubMedCrossRef

23.

Ling Q, Xie H, Lu D, Wei X, Gao F, Zhou L, et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol. 2013;58:271–7.PubMedCrossRef

24.

Li Z, Sun F, Hu Z, Xiang J, Zhou J, Yan S, et al. New-onset diabetes mellitus in liver transplant recipients with hepatitis C: analysis of the national database. Transplant Proc. 2016;48:138–44.PubMedCrossRef

25.

Ling Q, Xu X, Xie H, Wang K, Xiang P, Zhuang R, et al. New-onset diabetes after liver transplantation: a national report from China liver transplant registry. Liver Int. 2016;36:705–12.PubMedCrossRef

26.

Li DW, Lu TF, Hua XW, Dai HJ, Cui XL, Zhang JJ, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a meta-analysis. World J Gastroenterol. 2015;21:6329–40.PubMedPubMedCentralCrossRef

27.

Cho Y, Lee MJ, Choe EY, Jung CH, Joo DJ, Kim MS, et al. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. Liver Transpl. 2014;20:557–63.PubMedCrossRef

28.

Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl. 2007;13:136–44.PubMedCrossRef

29.

Couto CA, Gelape CL, Doycheva IB, Kish JK, Martin P, Levy C. Ethnicity predicts metabolic syndrome after liver transplant. Hepatol Int. 2013;7:741–8.PubMedCrossRef

30.

Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72:1066–72.PubMedCrossRef

31.

Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Rakela J, Vargas HE, et al. Pretransplant fasting glucose predicts new-onset diabetes after liver transplantation. J Transplant. 2012;2012:614781.PubMedPubMedCentralCrossRef

32.

Vaughn VM, Cron DC, Terjimanian MN, Gala ZS, Wang SC, Su GL, et al. Analytic morphomics identifies predictors of new-onset diabetes after liver transplantation. Clin Transplant. 2015;29:458–64.PubMedCrossRef

33.

Parolin MB, Zaina FE, Araújo MV, Kupka E, Coelho JC. Prevalence of new-onset diabetes mellitus in Brazilian liver transplant recipients: association with HCV infection. Transplant Proc. 2004;36:2776–7.PubMedCrossRef

34.

Pirsch JD, Henning AK, First MR, Fitzsimmons W, Gaber AO, Reisfield R, et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. Am J Transplant. 2015;15:1982–90.PubMedCrossRef

35.

Xue M, Lv C, Chen X, Liang J, Zhao C, Zhang Y, et al. Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation. J Diabetes Investig. 2017;8:181–7.PubMedCrossRef

36.

Ling Q, Xie H, Li J, Liu J, Cao J, Yang F, et al. Donor graft microRNAs: a newly identified player in the development of new-onset diabetes after liver transplantation. Am J Transplant. 2017;17:255–64.PubMedCrossRef

37.

Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-evidence from three different disease models: NAFLD HCV and HIV. World J Gastroenterol. 2016;22:9674–93.PubMedPubMedCentralCrossRef

38.

Linder KE, Baker WL, Rochon C, May ST, Sheiner PA, Martin ST. Evaluation of posttransplantation diabetes mellitus after liver transplantation: assessment of insulin administration as a risk factor. Ann Pharmacother. 2016;50:369–75.PubMedCrossRef

39.

Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191:5785–91.PubMedCrossRef

40.

Borel J, Feurer FC, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–75.PubMedCrossRef

41.

Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36[Suppl 2]:25S–32S.PubMedCrossRef

42.

Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695–7.PubMedCrossRef

43.

Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 1993;365:352–5.PubMedCrossRef

44.

Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 2010;285:40050–9.PubMedPubMedCentralCrossRef

45.

Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant. 2001;1:325–33.PubMedCrossRef

46.

Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345–9.PubMedCrossRef

47.

Ho IC, Kim JH, Rooney JW, Spiegelman BM, Glimcher LH. A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci USA. 1998;95:15537–41.PubMedPubMedCentralCrossRef

48.

Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol. 2000;20:6600–11.PubMedPubMedCentralCrossRef

49.

Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 2011;162:136–46.PubMedPubMedCentralCrossRef

50.

Auer V, Janas E, Ninichuk V, Eppler E, Weiss T, Kirchner S, et al. Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets. Clin Exp Immunol. 2012;170:238–47.PubMedPubMedCentralCrossRef

51.

Wang R, McGrath B, Kopp R, Roe M, Tang X, Chen G, et al. Insulin secretion and Ca2+ dynamics in β-cells are regulated by PERK eIF2α kinase in concert with calcineurin. J Biol Chem. 2013;288:33824–36.PubMedPubMedCentralCrossRef

52.

Rostambeigi N, Lanza I, Dzeja P, Deeds M, Irving B, Reddi H, et al. Unique cellular and mitochondrial defects mediate FK506- induced islet β-cell dysfunction. Transplantation. 2011;91:615–23.PubMedPubMedCentralCrossRef

53.

Düffer M, Drews P, Lembert N, Idahl L, Drews G. Diabetogenic effect of cyclosporin a is mediated by interference with mitochondrial function of pancreatic B-Cells. Mol Pharmacol. 2001;60:873–9.

54.

Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab. 2001;3:393–402.PubMedCrossRef

55.

Radu RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nabe K, et al. Tacrolimus suppresses glucose-induced insulin release frompancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab. 2005;288:E365–71.PubMedCrossRef

56.

Siemann G, Blume R, Grapentin D, Oetjen E, Schwaninger M, Knepel W. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. Mol Pharmacol. 1999;55:1094–100.PubMedCrossRef

57.

Furman B, Ong WK, Pyne NJ. Cyclic AMP signaling in pancreatic islets. Adv Exp Med Biol. 2010;654:281–304.PubMedCrossRef

58.

Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17:1575–80.PubMedPubMedCentralCrossRef

59.

Shivaswamy V, Bennett RG, Clure CC, Ottemann B, Davis JS, Larsen JL, et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Transl Res. 2014;163:221–31.PubMedCrossRef

60.

Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects ofimmunosuppressive agents. J Clin Endocrinol Metab. 2014;99:E1885–94.PubMedCrossRef

61.

Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12:2499–509.PubMedPubMedCentralCrossRef

62.

Haddad E, Saunders R, McAlister V, Renouf E, Malthaner R, Kjaer MS, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;18(4):CD005161. https://doi.org/10.1002/14651858.CD005161.pub2.

63.

Muduma G, Odeyemi I, Saunders R, Pollock R. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS One. 2016;11:e0160421.PubMedPubMedCentralCrossRef

64.

Fransson L, Rosengren V, Saha TK, Grankvist N, Islam T, Honkanen RE, et al. Mitogen-activated protein kinases and protein phosphatase 5 mediate glucocorticoid-induced cytotoxicity in pancreatic islets and β-cells. Mol Cell Endocrinol. 2014;383:126–36.PubMedCrossRef

65.

Colvin ES, Ma HY, Chen YC, Hernandez AM, Fueger PT. Glucocorticoid-induced suppression of β-cell proliferation is mediated by Mig6. Endocrinology. 2013;154:1039–46.PubMedPubMedCentralCrossRef

66.

Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54:1090–9.PubMedCrossRef

67.

Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia. 2005;48:2119–30.PubMedCrossRef

68.

Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998;47:3–6.PubMedCrossRef

69.

Rooney DP, Neely RD, Cullen C, Ennis CN, Sheridan B, Atkinson AB, et al. The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab. 1993;77:1180–3.PubMed

70.

Waldner M, Fantus D, Solari M, Thomson AW. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol. 2016;82:1158–70.PubMedPubMedCentralCrossRef

71.

Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014:1–45.CrossRef

72.

Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694–705.PubMedCrossRef

73.

Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252–62.PubMedCrossRef

74.

Ju WQ, Guo ZY, Liang WH, Wu LW, Tai Q, Hu AB, et al. Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety and after conversion to sirolimus their requirements of insulin decrease. Exp Clin Transplant. 2012;10:132–5.PubMedCrossRef

75.

Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2009;15:1834–42.PubMedCrossRef

76.

White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–44.PubMedPubMedCentralCrossRef

77.

Hui JM, Sud A, Farrel GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology. 2003;125:1695–704.PubMedCrossRef

78.

Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384–92.PubMedCrossRef

79.

Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61:S69–78.PubMedCrossRef

80.

Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8.PubMedCrossRef

81.

University of California, San Francisco division of transplantation: Liver transplant. https://transplant.surgery.ucsf.edu/conditions–procedures/liver-transplant.aspx. Accessed 20 Oct 2017.

82.

Craig K, Bell S, Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of more than 1.9 million individuals from 38 observational studies. Diabetes Care. 2005;38:1804–12.

83.

Jakobsen MU, Berentzen T, Sørensen TI, Overvad K. Abdominal obesity and fatty liver. Epidemiol Rev. 2007;29:77–87.PubMedCrossRef

84.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2017;68(2):335–52.PubMedCrossRef

85.

Gitto S, Villa E. Non-alcoholic fatty liver disease and metabolic syndrome after liver transplant. Int J Mol Sci. 2016;17:490.PubMedPubMedCentralCrossRef

86.

Zayed R, Bahgat M, Wahab M, El-Etreby S, Saad R, Elmorsy F. Prevalence and risk factors of new onset diabetes after liver transplantation (NODAT): a single Egyptian center experience. Arch Dig Disord. 2017;1:7.

87.

Roccaro G, Goldberg D, Hwang W, Judy R, Thomasson A, Kimmel S, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation. Am J Transplant. 2017;20:1.

88.

Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. https://doi.org/10.1186/s12876-015-0407-y PubMedPubMedCentralCrossRef

89.

Ahn HY, Cho YM, Yi NJ, Suh KS, Lee KU, Park KS, et al. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation. J Korean Med Sci. 2009;24:567–70.PubMedPubMedCentralCrossRef

90.

Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007;30:609–15.PubMedCrossRef

91.

Abe T, Onoe T, Tahara H, Tashiro H, Ishiyama K, Ide K. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. Transpl Proc. 2014;46:865–9.CrossRef

92.

Watt K, Pedersen R, Kremers W, Heimbach J, Charlton M. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10:1420–7.PubMedPubMedCentralCrossRef

93.

Moon J, Barbeito R, Faradji R, Gaynor J, Tzakis A. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation. 2006;82:1625–8.PubMedCrossRef

94.

Younossi Z, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85,000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686.PubMedCrossRef

95.

Liu FC, Lin JR, Chen HP, Tsai YF, Yu HP. Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: a population-based cohort study. Medicine (Baltimore). 2016;95:e3829.CrossRef

96.

Schoening W, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013;13:2384–94.PubMedCrossRef

97.

Bhati C, Idowu M, Sanyal A, Rivera M, Driscoll C, Stravitz R, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis. Transplantation. 2017;101:1867–74.PubMedCrossRef

98.

D’Avola D, Cuervas-Mons V, Martı J, Urbina J, Llado L, Jimenez C, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil. Liver Transpl. 2017;23:498.PubMedCrossRef

99.

Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B, et al. Liver cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2012;18:370–5.PubMedCrossRef

100.

John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl. 2002;8:708–13.PubMedCrossRef

101.

Navasa M, Bustamante J, Marroni C, Gonzalez E, Andrew H, Esmatjes E, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol. 1996;25:64–71.PubMedCrossRef

102.

Kuo H, Lum E, Martin P, Bunnapradist S. Effect of diabetes and acute rejection on liver transplant outcomes: an analysis of the organ procurement and transplantation network/united network for organ sharing database. Liver Transpl. 2016;22:796.PubMedCrossRef

103.

Morbitzer KA, Taber DJ, Pilch NA, Meadows HB, Fleming JN, Bratton CF, et al. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clin Transplant. 2014;28:862–8.PubMedCrossRef

104.

Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6:1922–9.PubMedCrossRef

105.

Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant. 1999;14:1244–6.PubMedCrossRef

106.

Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37–61.PubMedCrossRef

107.

Tokodai K, Amada N, Kikuchi H, Haga I, Takayama T, Nakamura A. Posttransplant increase of body mass index is associated with new-onset diabetes mellitus after kidney transplantation. Tohoku J Exp Med. 2013;229:227–32.PubMedCrossRef

108.

Ammori JB, Sigakis M, Englesbe MJ, O’Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res. 2007;140:227–33.PubMedCrossRef

109.

Wallia A, Parikh N, O’Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, et al. Glycemic control by a glucose management service and infection rates following liver transplantation. Endocr Pract. 2011;17:546–51.PubMedPubMedCentralCrossRef

110.

Park C, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation. 2009;81:1031–6.CrossRef

111.

Wallia A, Parikh N, Molitch M, Mahler E, Tian L, Huang J, et al. Post-transplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222–6.PubMedPubMedCentralCrossRef

112.

Pei D, Chen TW, Kuo YL, Hung YJ, Hsieh CH, Wu LY, et al. The effect of surgical stress on insulin sensitivity, glucose effectiveness and acute insulin response to glucose load. J Endocrinol Invest. 2003;26:397–402.PubMedCrossRef

113.

Keegan MT, Vrchota JM, Haala PM, Timm JV. Safety and effectiveness of intensive insulin protocol use in post-operative liver transplant recipients. Transplant Proc. 2010;42:2617–24.PubMedCrossRef

114.

Boerner B, Shivaswamy V, Goldner W, Larsen J. Management of the hospitalized transplant patient. Curr Diab Rep. 2015;15:19.PubMedPubMedCentralCrossRef

115.

VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015;35:2575–83.PubMedPubMedCentralCrossRef

116.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:479–97.PubMedCrossRef

117.

Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014;40:190–6.PubMedCrossRef

118.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2017. https://doi.org/10.1161/HYP.0000000000000065.

119.

Kim Y, Kim JR, Choi H, Hwang JW, Jang HR, Lee JE, et al. Patients with persistent new-onset diabetes after transplantation have greater weight gain after kidney transplantation. J Korean Med Sci. 2013;28:1431–4.PubMedPubMedCentralCrossRef

120.

Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353–8.PubMedCrossRef

121.

Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011;11:1376–81.PubMedCrossRef

122.

American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64–74.CrossRef

123.

Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18:483–8.PubMedCrossRef

124.

Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Therneau TM, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014;60:2008–16.PubMedPubMedCentralCrossRef

125.

Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14:979–84.PubMedCrossRef

126.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef

127.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metabol. 2005;90:501–6.CrossRef

128.

Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol. 2015;11:465–77.PubMedCrossRef

129.

Vanhove T, Remijsen Q, Kuypers D, Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando). 2017;31:69–77.CrossRef

130.

Sagedal S, Asberg A, Hartmann A, Bergan S, Berg KJ. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clin Transplant. 1998;12:553–6.PubMed

131.

Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol. 2003;2:401–14.PubMedCrossRef

132.

Türk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006;6:842–6.PubMedCrossRef

133.

Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin Transplant. 2007;21:246–51.PubMedCrossRef

134.

Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 2000;106:1305–7.PubMedPubMedCentralCrossRef

135.

Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135–8.PubMedCrossRef

136.

Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation. 2004;77:1009–14.PubMedCrossRef

137.

Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation. 2005;80:1402–5.PubMedCrossRef

138.

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. Arch Toxicol. 2016;90:1861–81.PubMedCrossRef

139.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRef

140.

Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30:463–84.PubMedCrossRef

141.

Sadhu AR, Schwartz SS, Herman ME. The rationale for use of incretins in the management of new onset diabetes after transplantation (NODAT). Endocr Pract. 2015;21:814–22.PubMedCrossRef

142.

Gámán G, Sárváry E, Gelley F, Doros A, Görög D, Fehérvári I, et al. New-onset diabetes mellitus and the analysis of dipeptidyl-peptidase-4 after liver transplantation. Transplant Proc. 2014;46:2177–80.PubMedCrossRef

143.

Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab. 2013;17:S203–5.PubMedPubMedCentralCrossRef

144.

Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14:115–23.PubMedCrossRef

145.

Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014;2014:617638.PubMedPubMedCentralCrossRef

146.

Bae J, Lee MJ, Choe EY, Jung CH, Wang HJ, Kim MS, et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study. Endocrinol Metab (Seoul). 2016;31:161–7.CrossRef

147.

Soliman AR, Fathy A, Khashab S, Shaheen N, Soliman MA. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. Exp Clin Transplant. 2013;11:494–8.PubMedCrossRef

148.

Cariou B. Pleiotropic effects of insulin and GLP-1 receptor agonists: potential benefits of the association. Diabetes Metab. 2015;41:6S28–35.PubMedCrossRef

149.

Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013;36:e171–2.PubMedPubMedCentralCrossRef

150.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG outcome investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef

151.

Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.PubMedCrossRef

152.

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the cvd-real study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–59.PubMedPubMedCentralCrossRef

153.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.PubMedCrossRef

154.

Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17:2601–16.PubMedCrossRef

155.

Muir CA, Greenfield JR, MacDonald PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantation. J Heart Lung Transplant. 2017;36:914–6.PubMedCrossRef

156.

Rajasekeran H, Kim SJ, Cardella CJ, Schiff J, Cattral M, Cherney DZI, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care. 2017;40:e75–6.PubMedCrossRef

157.

Wallia A, Schmidt K, Oakes DJ, Pollack T, Welsh N, Kling-Colson S, et al. Glycemic control reduces infections in post-liver transplant patients: results of a prospective randomized study. J Clin Endocrinol Metab. 2017;102:451–9.PubMed

158.

Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11:623–31.PubMedCrossRef

159.

Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complicat. 2015;29:295–301.PubMedCrossRef

160.

Meneghini LF. Insulin therapy for type 2 diabetes. Endocrine. 2013;43:529–34.PubMedCrossRef

161.

Dhanasekaran R. Management of immunosuppression in liver transplantation. Clin Liver Dis. 2017;21:337–53.PubMedCrossRef

162.

Hu AB, Wu LW, Tai Q, Zhu XF, He XS. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. J Dig Dis. 2013;14:38–44.PubMedCrossRef

163.

Ju WQ, Guo ZY, Ling X, He XS, Wu LW, Tai Q, et al. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients. Exp Clin Transplant. 2012;10:258–62.PubMedCrossRef

164.

Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, et al. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin Transplant. 2007;21:526–31.PubMedCrossRef

165.

Kim YK, Lee KW, Kim SH, Cho SY, Han SS, Park SJ. Early steroid withdrawal regimen prevents new-onset diabetes mellitus in old-age recipients after living donor liver transplantation. World J Surg. 2012;36:2443–8.PubMedCrossRef

166.

Meadows HB, Taber DJ, Pilch NA, Tischer SM, Baliga PK, Chavin KD. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients. Transplant Proc. 2012;44:1323–8.PubMedCrossRef

167.

Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Cochrane Database Syst Rev. 2015;15:1–96.

168.

Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233–9.PubMedCrossRef

169.

Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011;11:965–76.PubMedCrossRef

170.

Wang L, Li N, Wang MX, Lu SC. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study. Genet Mol Res. 2015;14:3191–9.PubMedCrossRef

171.

Emre S, Genyk Y, Schluger LK, Fishbein TM, Guy SR, Sheiner PA, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int. 2000;13:73–8.PubMedCrossRef

172.

Abouljoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS. Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant. 2002;16:168–72.PubMedCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date